The analysis of scRNA-Seq data from 8 patients with relapsed/refractory AML treated with AZA + nivolumab (36) confirmed enrichment of IED68 scores on CD4+ and CD8+ T cells, NK cells, and NK/T cell precursors (Supplemental Figure 25A). This evidence concerns the gene CD4 and acute myeloid leukemia.